Science
Lung Cancer Europe lung cancer NSCLC Elisa De Paolis
Photo: Depositphotos

How Do We Select the Best 2L Therapy for Advanced EGFR‑Mutant NSCLC After Osimertinib? – Oncogene Cancer Research

Oncogene Cancer Research shared a post on X:

“How do we select the best 2L therapy for advanced EGFR‑mutant NSCLC after osimertinib?

Dr. Julia Rotow outlines options by resistance mechanism, including the emerging amivantamab + lazertinib combo. Personalized strategies matter.”

Read Further.

More posts featuring Oncogene Cancer Research.

cancer Julia Rotow NSCLC OncoDaily Oncogene Cancer Research Oncology